白蛋白结合型紫杉醇治疗晚期恶性肿瘤的疗效与安全性研究

Efficacy and Safety of Nab-paclitaxel in Advanced Solid Tumor Patients

摘要:
目的观察白蛋白结合型紫杉醇治疗晚期恶性肿瘤的疗效和安全性。
方法 25例晚期恶性肿瘤患者接受含白蛋白结合型紫杉醇方案(白蛋白结合型紫杉醇130 mg/m^2, 第1天、第8天)每21 d为1周期, 至少2个周期后评价疗效。
结果 25例患者中总有效率56%(14/25), 临床受益率76%(19/25), 中位TTP5.6(2.1~11.6)个月。不良反应主要为中性粒细胞减少(12%), 外周神经损害(8%)和肌肉酸痛乏力(12%)。
结论白蛋白结合型紫杉醇方案治疗晚期恶性肿瘤疗效确切, 安全性良好。

Abstract:
Objective To evaluate the efficacy and the safety of nab-paclitaxel in advanced solid tumor patients.
Methods Twenty-five patients with solid tumor received nab-paclitaxel-based (nab-paclitaxel 130 mg/m2dl, 8) regimes every 3 wk. All of the patients were evaluated for efficacy and safety at least after 2 cycles.
Results Of the 25 patients, 14 had partial response whereas 5 had stable disease. The response and clinical benefit rates were 59% and 76%, respectively. The median time to progression was 5.6 months. The predominant toxicities were neutropaenia (12%), neuropathy (8%), and muscle pain (12%).
Conclusion The nab-paclitaxel-based regimen was effective and tolerable in advanced solid tumor.